Also known as REGN2477
An anti-activin-A antibody (Regeneron) — closest to approval of the axis (FOP), and a partner in obesity muscle-preservation combinations.
Garetosmab is a monoclonal antibody from Regeneron that neutralizes activin A — a TGF-β-superfamily ligand that, like myostatin, signals through the activin type II receptors. Blocking activin A widens the axis beyond myostatin alone, and garetosmab plays two roles in this catalog: it is the most clinically advanced agent here, and it is the third leg of the triple obesity combination.
Garetosmab’s lead indication is fibrodysplasia ossificans progressiva (FOP) — an ultra-rare disease in which soft tissue turns to bone, driven by activin A. Its Phase 3 OPTIMA trial was positive (roughly 90–94% reduction in new heterotopic bone lesions), and its FDA Biologics License Application was accepted for Priority Review with a decision target around August 2026 — making it the closest-to-approval molecule on this axis, albeit for a rare bone disease rather than obesity.
Its metabolic role is as the activin-A arm of the semaglutide + trevogrumab + garetosmab triple combination, which produced the best body-composition profile in early data. As an anti-activin-A antibody (~150 kDa), it illustrates that the "myostatin axis" is really a broader activin/ActRII network with multiple blockable nodes.
Binds and neutralizes activin A, blocking its signaling through ActRII. In bone disease this prevents activin-A-driven abnormal ossification; in the metabolic setting, adding activin-A blockade to myostatin blockade and incretin therapy further shifts body composition toward fat loss with preserved muscle.
Behind every vial of Garetosmab is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Garetosmab, specifically, is brought into being.
On paper, Garetosmab weighs in at roughly 150,000 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Garetosmab is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Garetosmab plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Garetosmab proves itself: identity confirmed by mass spectrometry against its ~150,000 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Garetosmab — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Garetosmab is a recombinant monoclonal antibody (~150 kDa) produced in mammalian cell culture, characterized with antibody-grade analytics (glycan/charge-variant profiling, mass spectrometry, binding/potency bioassay) — not a synthetic peptide.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Garetosmab, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
A Regeneron monoclonal antibody that neutralizes activin A. Its lead use is the rare bone disease FOP, and it is also a component of an obesity triple-combination aimed at preserving muscle.
Activin A signals through the same ActRII receptors as myostatin. Blocking it both prevents abnormal bone formation in FOP and, combined with myostatin blockade and a GLP-1 drug, shifts weight loss toward fat while sparing muscle.
No — this is a research and educational reference. Garetosmab’s obesity use is investigational; its FOP application was under FDA review.